Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) EPS (Weighted Average and Diluted) (2021 - 2026)

Kura Oncology (KURA) reported EPS (Weighted Average and Diluted) of -$0.83 for Q1 2026, down 25.76% year-over-year from -$1.12 in Q1 2025, and down 136.87% on a QoQ basis from $2.25 in Q4 2025.

Kura Oncology (KURA) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.83 in Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 25.76% year-over-year to -$0.83 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.34 (down 11.43% YoY) and the FY2025 annual result came in at -$3.18, down 57.43% from the prior year.
  • EPS (Weighted Average and Diluted) fell to -$0.83 in Q1 2026 per KURA's latest filing, from $2.25 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.25 in Q4 2025 and bottomed at -$0.85 in Q3 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.53 (2022), against an average of -$0.41.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 1123.24% in 2025, while the deepest fall reached 34.23% in 2025.
  • Tracing KURA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.49 in 2022, then declined by 12.24% to -$0.55 in 2023, then surged by 60.0% to -$0.22 in 2024, then surged by 1123.24% to $2.25 in 2025, then sank by 136.87% to -$0.83 in 2026.
  • Per Business Quant, the three latest KURA EPS (Weighted Average and Diluted) figures stand at -$0.83 (Q1 2026), $2.25 (Q4 2025), and -$0.85 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn -0.83

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.83
Dec 31, 2025 2.25
Sep 30, 2025 -0.85
Jun 30, 2025 -0.75
Mar 31, 2025 -0.66
Dec 31, 2024 -0.22
Sep 30, 2024 -0.63
Jun 30, 2024 -0.59
Mar 31, 2024 -0.59
Dec 31, 2023 -0.55
Sep 30, 2023 -0.50
Jun 30, 2023 -0.53
Mar 31, 2023 -0.50
Dec 31, 2022 -0.49
Sep 30, 2022 -0.53
Jun 30, 2022 -0.52
Mar 31, 2022 -0.49
Dec 31, 2021 -0.50
Sep 30, 2021 -0.50
Jun 30, 2021 -0.51